Fig. 1

Study flow diagram and subject disposition during 52 weeks of long-term treatment with lurasidone. Depressed episode group consisted of Japanese patients who had completed an initial 6 week, double-blind, placebo-controlled, evaluation of lurasidone. PBO to LUR = received placebo during prior 6 week trial followed by lurasidone (flexibly dosed 2–120 mg/day) in 52 week long-term trial. LUR to LUR = received lurasidone (flexibly dosed at either 20–60 or 80–120 mg/day) during prior 6 week trial followed by lurasidone (flexibly dosed 20 to 120 mg/day) in 52 week long-term trial. Non-depressed episode group consisted of Japanese patients with bipolar I disorder whose current or most recent episode was a mania, hypomania, or mixed episode. LUR lurasidone, PBO placebo